chartexchange

Fermenta Biotech Stock Jumps 60% in 3 Months; What Could Drive Further Growth for This Global Vitamin D3 Manufacturer?

Trade Brains | Oct 6, 2026 2:16 AM EDT

The global demand for Vitamin D3 is being supported by rising health awareness, increasing nutritional supplement adoption and growing concerns around Vitamin D deficiency. This has created opportunities for manufacturers serving pharmaceutical, nutraceutical and food applications.
Fermenta Biotech Ltd is one of the established players in this space, with a presence across international markets. The company is also expanding its product portfolio and manufacturing capacity as it looks to tap emerging opportunities in human nutrition and plant-based Vitamin D products.

Also read: Trent Shares Jump 13% After Reporting a Strong Q2 Update; Here Are 5 Important Takeaways for Investors

With a market capitalisation of Rs. 1,635 cr, the shares of Fermenta Biotech Ltd were trading at Rs. 555.60 per share, down from its previous close of Rs. 555.70 per share. The stock has delivered strong returns across different timeframes, rising 71% over the past year, 66% in six months, 60% in three months and 11% in the last month.
Strong Global Presence
Fermenta Biotech Ltd has established a strong position in the global Vitamin D3 market, with its products supplied across more than 60 countries. The company has a geographically diversified revenue base, with international markets contributing around 61% of total revenue in FY26, while domestic markets accounted for the remaining 39%. 
Europe contributed around 30% of revenue and North America around 13%, highlighting the company's exposure to developed international markets. Its long operating history, established customer relationships and backward-integrated manufacturing capabilities provide support to its position in the Vitamin D3 industry.
Vitamin D3 Remains the Core Business
Vitamin D3 continues to be the company's key product category, contributing more than 70% of revenue. The company manufactures different Vitamin D3 variants used across pharmaceuticals, dietary and nutritional supplements, food and beverage fortification, veterinary applications and animal feed. 

Also read: Nykaa’s Fashion and Beauty Segments Show Growth Signs; Is a Strong Q2 in the Picture?

This concentration makes the company's performance closely linked to Vitamin D3 demand, selling prices and volumes. In FY26, Fermenta's revenue from operations, excluding the real estate division, increased by around 26% year-on-year to Rs. 528 crore, supported by stronger Vitamin D3 volumes and favourable pricing in some segments.
Human Nutrition Demand Provides Growth Support
Human nutrition remains an important growth driver for Fermenta. Vitamin D3 API volumes for human nutrition increased around 21% year-on-year in FY26. The company is benefiting from increasing awareness about Vitamin D deficiency, rising health consciousness and greater adoption of nutritional supplements. Vitamin D3 is widely used in pharmaceutical formulations, nutraceuticals and dietary supplements, creating a broad demand base.
The company also expects demand from the human nutrition segment to remain supportive in the coming years. This could be important for Fermenta because the animal nutrition business is more exposed to commodity price volatility and competition from Chinese suppliers. A sustained increase in human nutrition volumes could therefore help the company improve its revenue mix and reduce some of the volatility associated with other Vitamin D3 applications.
VITADEE Green Could Open a New Growth Avenue
Fermenta is also looking to diversify beyond its conventional Vitamin D3 portfolio through its plant-based Vitamin D molecule, branded as VITADEE Green. The company received a process patent from the Indian Patents Office in September 2025 for the product and subsequently received FSSAI approval in July 2026 for its use in healthy supplements, nutraceuticals and food products.

Also read: Honasa Shares Surges 10% as Younger Brands Gain Momentum: Can Offline Expansion Strengthen Its Earnings Mix?

The product could help Fermenta target customers looking for plant-based alternatives in the nutrition and wellness market. While the contribution from VITADEE Green is expected to build gradually, successful commercialisation could provide the company with an additional growth avenue and broaden its customer base. The product also fits with the company's strategy of increasing the contribution of new products, including enzymes and other green chemistry molecules.
New Capacity Planned for VITADEE Green
To support the potential scale-up of VITADEE Green, Fermenta plans to invest around Rs. 67 crore in incremental manufacturing capacity from FY28. Around Rs. 53 crore of this investment is expected to be funded through debt. The proposed expansion will increase the company's manufacturing capability for the plant-based Vitamin D product and could allow it to cater to demand as commercial adoption increases.
Also read: 
The proposed capex comes at a time when Fermenta's balance sheet has improved significantly. Overall gearing stood at 0.29x as of March 31, 2026, compared with 0.33x a year earlier and 0.79x in FY23. Interest coverage also improved to 8.15x in FY26 from 4.45x in FY25. This provides the company with some financial flexibility to undertake the planned expansion while maintaining a relatively comfortable capital structure.
Profitability and Financial Position Have Improved
Fermenta's improved operating performance has also strengthened its financial profile. Its profit before interest, lease rental, depreciation and taxation (PBILDT) margin increased by around 380 basis points year-on-year to 19.55% in FY26. PBILDT rose to Rs. 103.17 crore from Rs. 66.27 crore in FY25, while interest coverage improved substantially.
The company's financial performance has benefited from higher Vitamin D3 volumes and the scale-up of other products. CARE Ratings expects the company's revenue growth to remain supported by demand from human nutrition and the expansion of newer products. The rating agency has upgraded Fermenta's long-term bank facility rating to CARE BBB+; Stable from CARE BBB; Stable and its short-term rating to CARE A2 from CARE A3+.
Key Risks to Watch
Despite the positive outlook, Fermenta remains exposed to several risks. Vitamin D3 accounts for more than 70% of revenue, creating product concentration risk. The animal nutrition business is particularly vulnerable to volatile prices and competition from China, which is a major supplier in the animal-feed grade segment. Animal feed contributed around 21% of revenue in FY26.

Also read: Lupin shares in focus after launching DCGI-approved triple-combination inhaler

The company also operates with a relatively high working-capital requirement. Its working-capital cycle increased to 132 days in FY26 from 113 days in FY25, mainly because of inventory and receivables. 
Regulatory compliance is another important factor, as Fermenta's manufacturing facilities require approvals from multiple regulatory authorities. Overall, the company's ability to sustain human nutrition growth, successfully scale VITADEE Green and diversify its product portfolio will be important factors in determining whether the recent improvement in its financial performance can continue.
 

Read original article